Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Neurotrophic Bioscience Inc.

This article was originally published in Start Up

Executive Summary

Despite setbacks by neuroscience companies Cephalon Inc. and Regeneron Pharmaceuticals Inc., the hope that neurotrophic factors will provide relief for millions of sufferers of neurodegenerative diseases, by slowing the progression of the disease, is alive and kicking. Neurotrophic Biosciences hopes to succeed where others have not by taking an approach that will apply combinations of highly specific neurotrophic factors, many of them newly discovered, to the treatment of neurodegenerative diseases.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

SC090051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel